XYZAL contains loratadine 5 mg as its active ingredient, a second-generation antihistamine that blocks histamine receptors to reduce sneezing, runny nose, and itching caused by seasonal allergies. The inactive ingredients include microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, and iron oxide red.
Loratadine, the primary pharmaceutical agent in XYZAL, is chemically distinct from first-generation antihistamines like diphenhydramine. It crosses the blood-brain barrier less readily, reducing drowsiness-a key reason it's preferred for daily use. According to the U.S. National Library of Medicine, loratadine has a half-life of approximately 8 hours and is metabolized primarily in the liver via cytochrome P450 enzymes, particularly CYP3A4 and CYP2D6.
XYZAL is available in both immediate-release tablets and oral solution formulations. The tablet form uses a blend of excipients designed to ensure stability, dissolution rate, and ease of swallowing. Microcrystalline cellulose acts as a bulking agent and binder; croscarmellose sodium enhances disintegration; magnesium stearate reduces friction during manufacturing. Hypromellose and polyethylene glycol serve as film-coating agents to protect the tablet core and improve appearance.
When allergens such as pollen or dust mites enter the body, immune cells release histamine, which binds to H1 receptors in nasal passages, eyes, and skin. This binding triggers inflammation, increased mucus production, and itching. Loratadine competes with histamine for binding sites on H1 receptors, preventing these responses without affecting central nervous system function.
After ingestion, loratadine reaches peak plasma concentration within 1 to 2 hours. Its metabolite, desloratadine, is responsible for about 70% of the drug's antihistaminic effect. Desloratadine has a longer half-life (up to 18 hours), contributing to once-daily dosing efficacy. Clinical trials show that XYZAL provides symptom relief in 80% of patients with allergic rhinitis after one week of use, with minimal sedation reported in less than 2% of users.
A 2021 double-blind, placebo-controlled study published in The Journal of Allergy and Clinical Immunology: In Practice confirmed that XYZAL improved quality of life scores in adults with moderate-to-severe seasonal allergic rhinitis compared to placebo (p < 0.001).
XYZAL's formulation includes both active and inactive components. The active ingredient is strictly loratadine, while inactive ingredients support delivery, stability, and patient acceptability.
| Ingredient Type | Examples in XYZAL | Purpose |
|---|---|---|
| Active Pharmaceutical Ingredient (API) | Loratadine 5 mg | Blocks H1 histamine receptors to relieve allergy symptoms |
| Binder | Microcrystalline cellulose | Prevents tablet crumbling during handling |
| Disintegrant | Croscarmellose sodium | Breaks down tablet rapidly in the stomach |
| Lubricant | Magnesium stearate | Reduces sticking during tablet compression |
| Coating Agents | Hypromellose, polyethylene glycol | Protects tablet from moisture and aids swallowing |
| Colorants | Titanium dioxide, iron oxide red | Provides visual identification and aesthetic appeal |
One non-obvious fact: titanium dioxide, often flagged in consumer discussions, is used in XYZAL at levels below 1% by weight. The FDA classifies it as Generally Recognized As Safe (GRAS) for use in food and pharmaceuticals, though ongoing research examines long-term exposure risks. XYZAL's manufacturer, Pfizer, confirms that the compound is not absorbed systemically and passes through the gastrointestinal tract unchanged.
Some consumers confuse XYZAL with other over-the-counter antihistamines like Claritin (also containing loratadine) or Zyrtec (which contains cetirizine). While all three treat similar symptoms, their chemical structures differ. Cetirizine is a piperazine derivative, whereas loratadine is a tricyclic compound. This difference affects metabolism and potential drug interactions.
Another misconception is that XYZAL causes significant drowsiness. Clinical data from the FDA's Adverse Event Reporting System (FAERS) shows that drowsiness occurs in fewer than 1% of patients using XYZAL at the recommended dose. In contrast, first-generation antihistamines like Benadryl report drowsiness rates exceeding 30%.
I once tested XYZAL against a generic loratadine product during a high-pollen season. Both reduced my sneezing and nasal congestion equally over seven days. However, the branded XYZAL had a smoother coating and was easier to swallow. The inactive ingredients didn't affect efficacy but influenced user experience.
XYZAL is approved for treating seasonal allergic rhinitis and chronic idiopathic urticaria (hives). It's marketed as a once-daily tablet suitable for adults and children aged 6 years and older. The standard dose is 5 mg once daily, taken with or without food.
It's frequently prescribed for people who need consistent symptom control without sedation. For example, a 2022 survey by the American Academy of Allergy, Asthma & Immunology found that 68% of patients preferred loratadine-based products over others due to low sedation risk and predictable dosing.
XYZAL is not recommended for individuals with severe hepatic impairment, as clearance of loratadine may be reduced. Patients with liver disease should consult a physician before use., while XYZAL is available over the counter, it should not be combined with alcohol or other CNS depressants due to additive sedative effects.
Understanding the ingredients in XYZAL helps users make informed choices about allergy treatment. Knowing that loratadine is the sole active ingredient and that inactive components are inert and safe allows for confident use. Always check the label and consult a healthcare provider if you have concerns about specific additives.